Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apadoline SCHEMBL7518667 | 1.00 | KMT2A (0.49) | KMT2AMEN1LMNASMN1; SMN2BCHE | |
| Apadoline SCHEMBL31300302 | 1.00 | KMT2A (0.49) | KMT2AMEN1LMNASMN1; SMN2BCHE | |
| Apadoline SCHEMBL29878314 | 1.00 | KMT2A (0.49) | KMT2AMEN1LMNASMN1; SMN2BCHE | |
| SCHEMBL9784875 | 0.99 | KMT2A (0.48) | KMT2AMEN1LMNASMN1; SMN2BCHE | |
| Apadoline SCHEMBL9332140 | 0.99 | KMT2A (0.48) | KMT2AMEN1LMNASMN1; SMN2BCHE | |
| SCHEMBL9501761 | 0.94 | SMN1; SMN2 (0.47) | KMT2AMEN1LMNASMN1; SMN2BCHE | |
| SCHEMBL9784910 | 0.94 | SMN1; SMN2 (0.47) | KMT2AMEN1LMNASMN1; SMN2BCHE | |
| Hydrochloric Acid SCHEMBL9784859 | 0.94 | SMN1; SMN2 (0.47) | KMT2AMEN1LMNASMN1; SMN2BCHE | |
| Hydrochloric Acid SCHEMBL9784902 | 0.93 | SMN1; SMN2 (0.46) | KMT2AMEN1LMNASMN1; SMN2BCHE | |
| Hydrochloric Acid SCHEMBL9784906 | 0.93 | SMN1; SMN2 (0.46) | KMT2AMEN1LMNASMN1; SMN2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | THE SCRIPPS RESEARCH INSTITUTE | 2025-05-22 | — | — | US | claimed |
| US-20250017846-A1 | TOPICAL ANALGESICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-01-16 | — | — | US | claimed |
| US-20200054594-A1 | PHARMACEUTICAL COMPOSITION CONTAINING MOR AGONIST AND KOR AGONIST, AND USES THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-02-20 | — | — | US | claimed |
| EP-3610874-A1 | PHARMACEUTICAL COMPOSITION CONTAINING MOR AGONIST AND KOR AGONIST, AND USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2020-02-19 | — | — | EP | claimed |
| CN-109982699-A | A kind of medical composition and its use of MOR agonist and KOR agonist | 江苏恒瑞医药股份有限公司 | 2019-07-05 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101432011-A | Method for regulating neurotransmitter systems by inducing counteradaptation | ALEXANDER MICHALOW (US) | 2009-05-13 | — | — | CN | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2006034343-A2 | methods for regulating neurotransmitter systems by inducing counteradaptationS | MICHALOW ALEXANDER (US) | 2006-03-30 | — | — | WO | claimed |
| US-20060069086-A1 | Methods for regulating neurotransmitter systems by inducing counteradaptations | MICHALOW ALEXANDER | 2006-03-30 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2001015678-A2 | TOPICAL USE OF KAPPA OPIOID AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-6191126-B1 | TOPICAL ADMINISTERING | ALCON LABORATORIES, INC. | 2001-02-20 | — | — | US | claimed |
| US-6174878-B1 | OR INTRANASAL COMPOSITION E.G., ASIMADOLINE (EMD-61753), ENADOLINE, BENZENEACETAMIDE, AS AN ANALGESIC FOR EAR INFECTION, SWIMMER'S EAR, ETC.; ACTIVATION OF SPECIFIC RECEPTORS SO NO SIDE EFFECTS | ALCON LABORATORIES, INC. | 2001-01-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054594-A1 | PHARMACEUTICAL COMPOSITION CONTAINING MOR AGONIST AND KOR AGONIST, AND USES THEREOF | OPRM1, OPRK1, OPRD1 | KMT2A 1586/4885MEN1 3969/4885LMNA 3727/4885 |
| US-20250017846-A1 | TOPICAL ANALGESICS | OPRK1, OPRL1, OPRM1 | KMT2A 2996/4885MEN1 4882/4885LMNA 4719/4885 |
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | MEF2D, TEAD2, TEAD1 | KMT2A 442/4885MEN1 4490/4885LMNA 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.